On 9/10/19, Revance Therapeutics Inc (NASDAQ: RVNC) stock enjoyed a major increase of 11.4%, closing at $12.55. Moreover, trading volume in this advance was unusually high at 160% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 18.4% during the last week.
Current PriceTarget Research Rating
RVNC’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.
Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Revance Therapeutics has a very low Appreciation Score of 7 and a very low Power Rating of 6, leading to the Lowest Value Trend Rating.
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.